您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报 (医学版) ›› 2024, Vol. 62 ›› Issue (5): 1-6.doi: 10.6040/j.issn.1671-7554.0.2024.0121

• 慢性气道疾病的精准个体化诊疗——专家综述 •    下一篇

气道上皮及其源性细胞因子与哮喘:思考与展望

张锦涛,董亮   

  1. 山东第一医科大学第一附属医院呼吸与危重症医学科 山东省呼吸疾病研究所, 山东 济南 250014
  • 发布日期:2024-05-29
  • 通讯作者: 董亮. E-mail:dl5506@126.com
  • 基金资助:
    国家自然科学基金(82270032);山东省重点研发计划(2021SFGC0504);济南市呼吸疾病临床医学研究中心(202132002);中华国际医学交流基金会呼吸疾病青年实用研究项目(Z-2017-24-2301)

Airway epithelium and epithelial-derived cytokines in asthma: reflection and outlook

ZHANG Jintao, DONG Liang   

  1. Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University, Shandong Institute of Respiratory Disease, Jinan 250014, Shandong, China
  • Published:2024-05-29

摘要: 气道上皮通过与免疫细胞的紧密互作精细调控并维持气道微环境的形成,在哮喘免疫病理进展过程中处于核心地位。气道上皮源性细胞因子被认为在触发和维持哮喘气道炎症中担任关键角色,成为目前哮喘新型药物研发的热门靶点。本文综述气道上皮及其源性细胞因子在哮喘中的作用及相关靶向药物研究进展,为相关研究提供新视角与新思考。

关键词: 气道上皮, 细胞因子, 哮喘, 靶向药物, 展望

Abstract: The airway epithelium plays a central role in the pathogenesis of asthma by tightly interacting with immune cells and finely regulating the formation of the airway microenvironment. Epithelial-derived cytokines have been recognized as key players in triggering and sustaining airway inflammation in asthma, making them attractive targets for the development of novel asthma drugs. This article provides an overview of the role of the airway epithelium and its derived cytokines in asthma, as well as the progress in research on targeted drugs, offering new perspectives and insights for related studies.

Key words: Airway epithelium, Cytokines, Asthma, Targeted medicine, Outlook

中图分类号: 

  • R562
[1] Albrecht M, Garn H, Buhl T. Epithelial-immune cell interactions in allergic diseases[J]. Eur J Immunol, 2024, 54(1): e2249982. doi: 10.1002/eji.202249982.
[2] Noureddine N, Chalubinski M, Wawrzyniak P. The role of defective epithelial barriers in allergic lung disease and asthma development[J]. J Asthma Allergy, 2022, 15: 487-504. doi: 10.2147/JAA.S324080.
[3] Chen CY, Wu KH, Guo BC, et al. Personalized medicine in severe asthma: from biomarkers to biologics[J]. Int J Mol Sci, 2023, 25(1): 182. doi: 10.3390/ijms25010182.
[4] Hellings PW, Steelant B. Epithelial barriers in allergy and asthma[J]. J Allergy Clin Immunol, 2020, 145(6): 1499-1509.
[5] Vieira Braga FA, Kar G, Berg M, et al. A cellular census of human lungs identifies novel cell states in health and in asthma[J]. Nat Med, 2019, 25(7): 1153-1163.
[6] Zhang N, Xu J, Jiang C, et al.Neuro-immune regulation in inflammation and airway remodeling of allergic asthma[J]. Front Immunol, 2022, 13: 894047. doi: 10.3389/fimmu.2022.894047.
[7] Kohanski MA, Workman AD, Patel NN, et al. Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2018, 142(2): 460-469.e7.
[8] Waghray A, Monga I, Lin B, et al. A deep lung cell atlas reveals cytokine-mediated lineage switching of a rare cell progenitor of the human airway epithelium[J]. bioRxiv, 2023. doi: 10.1101/2023.11.28.569028.
[9] Gauvreau GM, Obyrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses[J]. N Engl J Med, 2014, 370(22): 2102-2110.
[10] Barlow JL, Peel S, Fox J, et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes(type 2 innate lymphoid cells)and airway contraction[J]. J Allergy Clin Immunol, 2013, 132(4): 933-941.
[11] Duchesne M, Okoye I, Lacy P. Epithelial cell alarmin cytokines: frontline mediators of the asthma inflammatory response[J]. Front Immunol, 2022, 13: 975914. doi: 10.3389/fimmu.2022.975914.
[12] Liu T, Liu Y, Miller M, et al. Autophagy plays a role in FSTL1-induced epithelial mesenchymal transition and airway remodeling in asthma[J]. Am J Physiol Lung Cell Mol Physiol, 2017, 313(1): L27-L40.
[13] Zhang J, Zhang D, Pan Y, et al. The TL1A-DR3 axis in asthma: membrane-bound and secreted TL1A co-determined the development of airway remodeling[J]. Allergy Asthma Immunol Res, 2022, 14(2): 233-253.
[14] Liu F, Zhang J, Zhang D, et al. Follistatin-related protein 1 in asthma: miR-200b-3p interactions affect airway remodeling and inflammation phenotype[J]. Int Immunopharmacol, 2022, 109: 108793. doi: 10.1016/j.intimp.2022.108793.
[15] Guo Z, Wu J, Zhao J, et al. IL-33 promotes airway remodeling and is a marker of asthma disease severity[J]. J Asthma, 2014, 51(8): 863-869.
[16] Cao L, Liu F, Liu Y, et al. TSLP promotes asthmatic airway remodeling via p38-STAT3 signaling pathway in human lung fibroblast[J]. Exp Lung Res, 2018, 44(6): 288-301.
[17] Zhang J, Dong L. Status and prospects: personalized treatment and biomarker for airway remodeling in asthma[J]. J Thorac Dis, 2020, 12(10): 6090-6101.
[18] Andreasson LM, Dyhre-Petersen N, Hvidtfeldt M, et al. Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation[J]. J Allergy Clin Immunol, 2023: S0091-6749(23)02409-0. doi: 10.1016/j.jaci.2023.11.915.
[19] Chatziparasidis G, Bush A, Chatziparasidi MR, et al. Airway epithelial development and function: a key player in asthma pathogenesis?[J]. Paediatr Respir Rev, 2023, 47: 51-61. doi: 10.1016/j.prrv.2023.04.005.
[20] Frey A, Lunding LP, Ehlers JC, et al. More than just a barrier: the immune functions of the airway epithelium in asthma pathogenesis[J]. Front Immunol, 2020, 11: 761. doi: 10.3389/fimmu.2020.00761.
[21] Basil MC, Katzen J, Engler AE, et al. The cellular and physiological basis for lung repair and regeneration: past, present, and future[J]. Cell Stem Cell, 2020, 26(4): 482-502.
[22] Basil MC, Cardenas-Diaz FL, Kathiriya JJ, et al. Human distal airways contain a multipotent secretory cell that can regenerate alveoli[J]. Nature, 2022, 604(7904): 120-126.
[23] Smolinska S, Antolín-Amérigo D, Popescu FD, et al. Thymic stromal lymphopoietin(TSLP), its isoforms and the interplay with the epithelium in allergy and asthma[J]. Int J Mol Sci, 2023, 24(16): 12725. doi: 10.3390/ijms241612725.
[24] Chen W, Chen S, Yan C, et al. Allergen protease-activated stress granule assembly and gasdermin D fragmentation control interleukin-33 secretion[J]. Nat Immunol, 2022, 23(7): 1021-1030.
[25] Zhang D, Zhang J, Xu C, et al. A humanized mouse model to study asthmatic airway remodeling and Muc-5ac secretion via the human IL-33[J]. Allergy, 2024. 79(5): 1364-1367.
[26] Qi Q, Xu J, Wang Y, et al. Decreased sphingosine due to down-regulation of acid ceramidase expression in airway of bronchiectasis patients: a potential contributor to pseudomonas aeruginosa infection[J]. Infect Drug Resist, 2023, 16: 2573-2588. doi: 10.2147/IDR.S407335.
[27] Saikumar Jayalatha AK, Jonker MR, Carpaij OA, et al. Lack of a transcriptional response of primary bronchial epithelial cells from patients with asthma and controls to IL-33[J]. Am J Physiol Lung Cell Mol Physiol, 2024, 326(1): L65-L70.
[28] Ruhl A, Antão AV, Dietschmann A, et al. STAT6-induced production of mucus and resistin-like molecules in lung Club cells does not protect against helminth or influenza A virus infection[J]. Eur J Immunol, 2024, 54(1): e2350558. doi: 10.1002/eji.202350558.
[29] Li Y, Zhang Q, Li L, et al. LKB1 deficiency upregulates RELM-α to drive airway goblet cell metaplasia[J]. Cell Mol Life Sci, 2021, 79(1): 42. doi: 10.1007/s00018-021-04044-w.
[30] Kortekaas RK, Geillinger-Kästle KE, Borghuis T, et al. Interleukin-11 disrupts alveolar epithelial progenitor function[J]. ERJ Open Res, 2023, 9(3): 00679-2022. doi: 10.1183/23120541.00679-2022.
[31] Thomas D, Mcdonald VM, Pavord ID, et al. Asthma remission: what is it and how can it be achieved?[J]. Eur Respir J, 2022, 60(5): 2102583. doi: 10.1183/13993003.02583-2021.
[32] Mümmler C, Milger K. Biologics for severe asthma and beyond[J]. Pharmacol Ther, 2023, 252: 108551. doi: 10.1016/j.pharmthera.2023.108551.
[33] Chan R, Stewart K, Misirovs R, et al. Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma[J]. J Allergy Clin Immunol Pract, 2022, 10(6): 1497-1505.
[34] Shinkai M, Yabuta T. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma[J]. Immunotherapy, 2023, 15(17): 1435-1447.
[35] Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma[J]. N Engl J Med, 2021, 385(18): 1656-1668.
[36] Maspero J, Agache IO, Kamei T, et al. Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial[J]. Respir Res, 2021, 22(1): 311. doi: 10.1186/s12931-021-01904-8.
[37] Eger K, Kroes JA, Ten Brinke A, et al. Long-term therapy response to anti-IL-5 biologics in severe asthma-a real-life evaluation[J]. J Allergy Clin Immunol Pract, 2021, 9(3): 1194-1200.
[38] Demarche SF, Schleich FN, Paulus VA, et al. Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers?[J]. Respir Res, 2017, 18(1): 133. doi: 10.1186/s12931-017-0615-9.
[39] Gautam S, Chu JH, Cohen AJ, et al. Sputum alarmins delineate distinct T2 cytokine pathways and unique subtypes of patients with asthma[J]. Allergy, 2023, 78(12): 3274-3277.
[40] Banno A, Reddy AT, Lakshmi SP, et al. Bidirectional interaction of airway epithelial remodeling and inflammation in asthma[J]. Clin Sci(Lond), 2020, 134(9): 1063-1079.
[41] Vannella KM, Ramalingam TR, Borthwick LA, et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis[J]. Sci Transl Med, 2016, 8(337): 337ra65. doi: 10.1126/scitranslmed.aaf1938.
[1] 张秋萍,朱慧志,吕川,夏咏琪,张秀. 基于生物信息学分析鉴定哮喘潜在的关键自噬和铁死亡相关基因[J]. 山东大学学报 (医学版), 2026, 64(1): 74-87.
[2] 张政,王建伟,杨玉娟,张宇,宋西成. 哮喘儿童2008及2019年免疫球蛋白E变化及相关危险因素[J]. 山东大学学报 (医学版), 2025, 63(7): 32-36.
[3] 曹洛菲,王珊珊,王金荣,姜荷云,苗瑜,马光增. 哮喘发作期FeNO升高儿童肺功能舒张试验的特点分析[J]. 山东大学学报 (医学版), 2025, 63(6): 38-44.
[4] 孙丛丛,崔文静,张锦涛,张东,刘晓菲,潘云,亓倩,徐嘉蔚,曾荣,郭红喜,董亮. 铁死亡在支气管哮喘气道重塑中的作用[J]. 山东大学学报 (医学版), 2024, 62(7): 1-9.
[5] 王静,刘晓菲,曾荣,许长娟,张锦涛,董亮. 基于机器学习算法鉴定哮喘的坏死性凋亡相关生物标志物[J]. 山东大学学报 (医学版), 2024, 62(7): 21-32.
[6] 闫金燕,杨春,李雷,吴福玲,焦永莉,张晓蔚,李晶,张瑞珍,王磊,马香. 山东省儿童百日咳感染与哮喘的相关性[J]. 山东大学学报 (医学版), 2024, 62(7): 33-41.
[7] 丁伊人,刘婉莹,姚蕾,姚欣. 大环内酯类抗生素治疗哮喘的研究进展[J]. 山东大学学报 (医学版), 2024, 62(5): 21-27.
[8] 王婷,张丽,王刚. 神经心理性哮喘[J]. 山东大学学报 (医学版), 2024, 62(5): 28-34.
[9] 徐芳,田国雄,孙倍倍,陈馨怡,陈高莹,张睿琦,应颂敏,吴妙莲,张超,吴优倩. 重度哮喘的生物与细胞疗法研究进展[J]. 山东大学学报 (医学版), 2024, 62(5): 35-42.
[10] 石硕川,曾荣,张锦涛,张东,潘云,刘晓菲,许长娟,王莹,董亮. 基于生物信息学探索支气管哮喘中的潜在差异免疫基因和免疫浸润特征[J]. 山东大学学报 (医学版), 2024, 62(5): 43-53.
[11] 徐新军,邵丽婷,陈颖,刘会芳,杨玉娟,张宇,王浛睿,宋西成. SYN008与Xolair®对过敏性哮喘小鼠治疗作用效果比较:炎症与重塑[J]. 山东大学学报 (医学版), 2024, 62(12): 1-10.
[12] 曹原,张剑桥,孟祥伟,刘文,庞晓明. 治疗慢性鼻窦炎伴鼻息肉的国内药物临床研究现状[J]. 山东大学学报 (医学版), 2024, 62(12): 38-42.
[13] 浩妍,崔丽梅,陈颖,杨玉娟,宋西成. 代谢组学在气道炎症性疾病中的应用[J]. 山东大学学报 (医学版), 2024, 62(12): 117-124.
[14] 吴飞,李清丽,肖振卫. 孟德尔随机化探究细胞因子与慢性肾脏病的因果关系[J]. 山东大学学报 (医学版), 2024, 62(11): 85-95.
[15] 祁少俊,唐延金,张正铎,吴虹,张佳程,秦川,刘锐,高希宝. 补充多种微量元素对高糖饮食大鼠的保护作用[J]. 山东大学学报 (医学版), 2023, 61(7): 19-26.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!